Cara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Tvardi Therapeutics

07/08/2023 23:01

* Cara Therapeutics Inc  CARA.OQ  reported a quarterly
adjusted
loss of 58 cents​​ per share for the quarter ended in June. The
mean expectation of seven analysts for the quarter was for a
loss of 54 cents per share.
    * Revenue fell 69.9% to $6.93 million from a year ago;
analysts
expected $6.56 million. 
    * Cara Therapeutics Inc's reported EPS for the quarter was a
loss
of 58 cents​.
    * The mean earnings estimate of analysts had fallen by
about 4.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Cara Therapeutics Inc shares had risen by 10.6% this
quarter and
lost 70.9% so far this year.
    * The company reported a quarterly loss of $31.48 million.
    * Wall Street's median 12-month price target for Cara
Therapeutics
Inc is $18.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 7 at 10:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.54          -0.58          Missed
 Mar. 31 2023      -0.52          -0.49          Beat
 Dec. 31 2022      -0.32          -0.56          Missed
 Sep. 30 2022      -0.42          -0.43          Missed